{"nctId":"NCT01335399","briefTitle":"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma","startDateStruct":{"date":"2011-08-04","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"count":748,"armGroups":[{"label":"Lenalidomide + Dexamethasone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lenalidomide","Drug: Dexamethasone"]},{"label":"Lenalidomide + Dexamethasone + Elotuzumab","type":"EXPERIMENTAL","interventionNames":["Drug: Lenalidomide","Drug: Dexamethasone","Biological: Elotuzumab (BMS-901608; HuLuc63)"]}],"interventions":[{"name":"Lenalidomide","otherNames":["Revlimid®"]},{"name":"Dexamethasone","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"]},{"name":"Dexamethasone","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"]},{"name":"Dexamethasone","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"]},{"name":"Dexamethasone","otherNames":["Decadron®","Dexamethasone Intensol®","Dexpak®","Taperpak®"]},{"name":"Elotuzumab (BMS-901608; HuLuc63)","otherNames":[]},{"name":"Elotuzumab (BMS-901608; HuLuc63)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.\n\nInclusion Criteria:\n\n* Subjects who are newly diagnosed with symptomatic Multiple Myeloma (MM) and who:\n\n  * have not received any prior systemic anti-myeloma therapy AND\n  * have measurable disease AND\n  * are not candidates for high-dose therapy plus stem-cell transplantation (SCT) because of age (≥ 65 years) or coexisting conditions. Refusal to undergo high dose therapy with SCT is NOT sufficient for entry onto CA204006 for a subject \\< 65 years old. There must be a comorbidity that prevents SCT for a subject \\< 65 years old\n\nExclusion Criteria:\n\n* Subjects with non-secretory or oligo-secretory or free light-chain only myeloma\n* Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions\n* Monoclonal Gammopathy of Undetermined Significance (MGUS)\n* Active plasma cell leukemia\n* Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS)","description":"PFS is defined as the time from randomization to the date of the first documented tumor progression (as determined by the Independent Review Committee (IRC)) or death due to any cause.\n\nThe IRC conducted a blinded, independent review of the tumor assessments based on the European Group for Blood and Bone Marrow Transplant (EBMT) criteria.\n\nCensoring rules applied:\n\n* Participants receiving subsequent systemic anti-myeloma therapy prior to documented progression were censored at the date of the last adequate tumor assessment prior to new therapy.\n* Participants who had an event (progression or death) \\> 10 weeks after their last tumor assessment were censored at their last adequate tumor assessment prior to the event.\n* Participants without progression or death (and not receiving subsequent therapy prior to progression) were censored at their last adequate tumor assessment.\n* Participants without any post-baseline tumor assessments were censored on the date of randomization","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.38","spread":null},{"groupId":"OG001","value":"29.47","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"ORR is defined as the percentage of participants with objective response among all randomized subjects. Participants with an objective response are those participants experiencing a partial response (PR) or better, based on Independent Review Committee (IRC) assessment, as per EBMT criteria.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.9","spread":null},{"groupId":"OG001","value":"79.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Survival is defined as the time from randomization to the date of death. A participant who did not die had his or her survival duration censored at the date of last contact ('last known date alive\").","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.42","spread":null},{"groupId":"OG001","value":"57.56","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline of Pain Severity Score and Pain Interference Score","description":"Pain severity (sensory dimension) and pain interference (reactive dimension, assessing the degree to which pain interferes with function) are measured using the Brief Pain Inventory- Short Form (BPI-SF).\n\nBPI-SF numeric rating scale goes from 0 (No pain) to 10 (Pain as bad as you can imagine).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"2.645"},{"groupId":"OG001","value":"-0.25","spread":"2.721"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"3.077"},{"groupId":"OG001","value":"-0.18","spread":"3.082"}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) Rate at Specific Time-points","description":"PFS rate is defined as the percentage of participants experiencing PFS at the defined time-points.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":null},{"groupId":"OG001","value":"0.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":null},{"groupId":"OG001","value":"0.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":null},{"groupId":"OG001","value":"0.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":null},{"groupId":"OG001","value":"0.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":null},{"groupId":"OG001","value":"0.25","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":293,"n":371},"commonTop":["Diarrhoea","Fatigue","Oedema peripheral","Anaemia","Constipation"]}}}